BACKGROUND: This study examined the value of serum p53 autoantibodies (p53-AAb) as detection and prognostic biomarkers in ovarian cancer. METHODS: p53-AAb were detected by ELISA in sera obtained preoperatively from women undergoing surgery for a pelvic mass. This group included women subsequently diagnosed with invasive serous ovarian cancer (n = 60), nonserous ovarian cancers (n = 30), and women with benign disease (n = 30). Age-matched controls were selected from the general population (n = 120). Receiver operating characteristic curves were constructed to compare the values of p53-AAb, CA 125, and HE4 as a screening biomarker. Kaplan-Meier curves and Cox proportional hazards modeling were used to assess its prognostic value on survival. RESULTS: p53-AAb were detected in 25 of 60 (41.7%) of serous cases, 4 of 30 (13.3%) nonserous cases, 3 of 30 (10%) benign disease cases, and 10 of 120 (8.3%) controls (combined P = 0.0002). p53-AAb did not significantly improve the detection of cases [area under the curve (AUC), 0.69] or the discrimination of benign versus malignant disease (AUC, 0.64) compared with CA 125 (AUC, 0.99) or HE4 (AUC, 0.98). In multivariate analysis among cases, p53-AAb correlated only with a family history of breast cancer (P = 0.01). Detectable p53 antibodies in pretreatment sera were correlated with improved overall survival (P = 0.04; hazard ratio, 0.57; 95% confidence interval, 0.33-0.97) in serous ovarian cancer. CONCLUSIONS: Antibodies to p53 are detected in the sera of 42% of patients with advanced serous ovarian cancer. IMPACT: Although their utility as a preoperative diagnostic biomarker, beyond CA 125 and HE4, is limited, p53-AAb are prognostic for improved overall survival.
BACKGROUND: This study examined the value of serum p53 autoantibodies (p53-AAb) as detection and prognostic biomarkers in ovarian cancer. METHODS:p53-AAb were detected by ELISA in sera obtained preoperatively from women undergoing surgery for a pelvic mass. This group included women subsequently diagnosed with invasive serous ovarian cancer (n = 60), nonserous ovarian cancers (n = 30), and women with benign disease (n = 30). Age-matched controls were selected from the general population (n = 120). Receiver operating characteristic curves were constructed to compare the values of p53-AAb, CA 125, and HE4 as a screening biomarker. Kaplan-Meier curves and Cox proportional hazards modeling were used to assess its prognostic value on survival. RESULTS:p53-AAb were detected in 25 of 60 (41.7%) of serous cases, 4 of 30 (13.3%) nonserous cases, 3 of 30 (10%) benign disease cases, and 10 of 120 (8.3%) controls (combined P = 0.0002). p53-AAb did not significantly improve the detection of cases [area under the curve (AUC), 0.69] or the discrimination of benign versus malignant disease (AUC, 0.64) compared with CA 125 (AUC, 0.99) or HE4 (AUC, 0.98). In multivariate analysis among cases, p53-AAb correlated only with a family history of breast cancer (P = 0.01). Detectable p53 antibodies in pretreatment sera were correlated with improved overall survival (P = 0.04; hazard ratio, 0.57; 95% confidence interval, 0.33-0.97) in serous ovarian cancer. CONCLUSIONS: Antibodies to p53 are detected in the sera of 42% of patients with advanced serous ovarian cancer. IMPACT: Although their utility as a preoperative diagnostic biomarker, beyond CA 125 and HE4, is limited, p53-AAb are prognostic for improved overall survival.
Authors: F D Vogl; E Stickeler; M Weyermann; T Köhler; H J Grill; G Negri; R Kreienberg; I B Runnebaum Journal: Oncology Date: 1999-11 Impact factor: 2.935
Authors: Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates Journal: Gynecol Oncol Date: 2008-10-12 Impact factor: 5.482
Authors: Miyun Tsai-Turton; Antonio Santillan; Dan Lu; Robert E Bristow; Kwun C Chan; Ie-Ming Shih; Richard B S Roden Journal: Gynecol Oncol Date: 2009-04-26 Impact factor: 5.482
Authors: Greg P Bertenshaw; Ping Yip; Partha Seshaiah; Jinghua Zhao; Tzong-Hao Chen; Wesley S Wiggins; James P Mapes; Brian C Mansfield Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-10 Impact factor: 4.254
Authors: Joseph J Otto; Crystal L Daniels; Lindsay N Schambeau; Brittany N Williams; Jana M Rocker; Lewis K Pannell Journal: Glycoconj J Date: 2018-06-09 Impact factor: 2.916
Authors: Benjamin A Katchman; Diego Chowell; Garrick Wallstrom; Allison F Vitonis; Joshua LaBaer; Daniel W Cramer; Karen S Anderson Journal: Gynecol Oncol Date: 2017-04-18 Impact factor: 5.482
Authors: A Oaknin; R Guarch; P Barretina; D Hardisson; A González-Martín; X Matías-Guiu; A Pérez-Fidalgo; B Vieites; I Romero; J Palacios Journal: Clin Transl Oncol Date: 2017-08-16 Impact factor: 3.405
Authors: Rudolf Kaaks; Renée Turzanski Fortner; Anika Hüsing; Myrto Barrdahl; Marika Hopper; Theron Johnson; Anne Tjønneland; Louise Hansen; Kim Overvad; Agnès Fournier; Marie-Christine Boutron-Ruault; Marina Kvaskoff; Laure Dossus; Mattias Johansson; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Carlo La Vecchia; Sabina Sieri; Amalia Mattiello; Domenico Palli; Rosario Tumino; Giuseppe Matullo; N Charlotte Onland-Moret; Inger T Gram; Elisabete Weiderpass; Maria-Jose Sánchez; Carmen Navarro Sanchez; Eric J Duell; Eva Ardanaz; Nerea Larranaga; Eva Lundin; Annika Idahl; Karin Jirström; Björn Nodin; Ruth C Travis; Elio Riboli; Melissa Merritt; Dagfinn Aune; Kathryn Terry; Daniel W Cramer; Karen S Anderson Journal: Int J Cancer Date: 2018-03-08 Impact factor: 7.396
Authors: Paul Sabbatini; Philipp Harter; Giovanni Scambia; Jalid Sehouli; Werner Meier; Pauline Wimberger; Klaus H Baumann; Christian Kurzeder; Barbara Schmalfeldt; David Cibula; Mariusz Bidzinski; Antonio Casado; Andrea Martoni; Nicoletta Colombo; Robert W Holloway; Luigi Selvaggi; Andrew Li; Jose del Campo; Karel Cwiertka; Tamas Pinter; Jan B Vermorken; Eric Pujade-Lauraine; Simona Scartoni; Monica Bertolotti; Cecilia Simonelli; Angela Capriati; Carlo Alberto Maggi; Jonathan S Berek; Jacobus Pfisterer Journal: J Clin Oncol Date: 2013-03-11 Impact factor: 44.544